BMTCN EXAM NEWEST 2026 ACTUAL EXAM TEST
BANK| BMTCN EXAM PREP WITH COMPLETE 850 REAL
EXAM QUESTIONS AND CORRECT DETAILED ANSWERS
(VERIFIED ANSWERS) ALREADY GRADED A+ (MOST
RECENT!!)
Q1. The primary goal of hematopoietic stem cell
transplantation (HSCT) is to:
A. Treat opportunistic infections
B. Replace diseased bone marrow with healthy stem cells
C. Provide lifelong immunosuppressive therapy
D. Reduce the side effects of chemotherapy
Correct Answer: B
Rationale: HSCT aims to restore normal hematopoiesis by
replacing defective or diseased marrow with healthy donor or
autologous stem cells. This restores the patient's ability to
produce healthy blood cells and, in malignant diseases, provides
a graft-versus-malignancy effect .
1
,Q2. Which of the following represents the most significant
change to the BMTCN examination beginning in January
2026?
A. The elimination of all questions about graft-versus-host disease
B. The name change to TCTCN™ and increased cellular therapy
content
C. Reduced eligibility requirements for RN licensure
D. A new requirement for 5,000 practice hours instead of 2,000
Correct Answer: B
Rationale: Effective January 2026, the BMTCN® examination has
been renamed to TCTCN™ (Transplantation and Cellular
Therapy Certified Nurse). The test content outline has been
updated to include more questions about cellular therapy,
reflecting the evolution of transplant and cellular therapy nursing
practice .
Q3. A nurse is preparing a patient for an autologous stem cell
transplant. Which statement accurately describes this type of
transplant?
2
,A. Stem cells are collected from an HLA-matched sibling
B. The patient receives their own previously collected stem cells
C. Stem cells are obtained from an unrelated volunteer donor
D. Umbilical cord blood is the only source of stem cells
Correct Answer: B
Rationale: Autologous transplantation uses the patient's own stem
cells, which are collected during remission, cryopreserved, and
reinfused after high-dose conditioning therapy. This approach
eliminates the risk of graft-versus-host disease .
Q4. A patient with multiple myeloma is scheduled for an
autologous stem cell transplant. The nurse understands that
this is the preferred transplant type for this diagnosis because:
A. Myeloma is highly responsive to the graft-versus-myeloma
effect
B. Autologous transplant eliminates the risk of GVHD while
allowing dose-intensive therapy
C. Allogeneic transplant is not possible for myeloma patients
D. Autologous transplant requires no conditioning therapy
Correct Answer: B
3
, Rationale: Autologous transplants are often used in multiple
myeloma and certain lymphomas because the patient's own stem
cells can be collected, treated, and reinfused. This approach
eliminates GVHD risk while allowing the delivery of high-dose
therapy .
Q5. The administration of Epstein-Barr virus (EBV) cytotoxic T-
lymphocytes has been found to be a feasible therapeutic
option in which EBV-mediated disease process?
A. Neuroblastoma
B. Lymphoproliferative disease
C. Nasopharyngeal rhabdomyosarcoma
D. Acute lymphocytic leukemia
Correct Answer: B
Rationale: Clinical studies have demonstrated the feasibility and
safety of administering Epstein-Barr virus (EBV) cytotoxic T-
lymphocytes (CTL) to prevent and treat EBV lymphoproliferative
disease in post-allogeneic transplant patients .
4
BANK| BMTCN EXAM PREP WITH COMPLETE 850 REAL
EXAM QUESTIONS AND CORRECT DETAILED ANSWERS
(VERIFIED ANSWERS) ALREADY GRADED A+ (MOST
RECENT!!)
Q1. The primary goal of hematopoietic stem cell
transplantation (HSCT) is to:
A. Treat opportunistic infections
B. Replace diseased bone marrow with healthy stem cells
C. Provide lifelong immunosuppressive therapy
D. Reduce the side effects of chemotherapy
Correct Answer: B
Rationale: HSCT aims to restore normal hematopoiesis by
replacing defective or diseased marrow with healthy donor or
autologous stem cells. This restores the patient's ability to
produce healthy blood cells and, in malignant diseases, provides
a graft-versus-malignancy effect .
1
,Q2. Which of the following represents the most significant
change to the BMTCN examination beginning in January
2026?
A. The elimination of all questions about graft-versus-host disease
B. The name change to TCTCN™ and increased cellular therapy
content
C. Reduced eligibility requirements for RN licensure
D. A new requirement for 5,000 practice hours instead of 2,000
Correct Answer: B
Rationale: Effective January 2026, the BMTCN® examination has
been renamed to TCTCN™ (Transplantation and Cellular
Therapy Certified Nurse). The test content outline has been
updated to include more questions about cellular therapy,
reflecting the evolution of transplant and cellular therapy nursing
practice .
Q3. A nurse is preparing a patient for an autologous stem cell
transplant. Which statement accurately describes this type of
transplant?
2
,A. Stem cells are collected from an HLA-matched sibling
B. The patient receives their own previously collected stem cells
C. Stem cells are obtained from an unrelated volunteer donor
D. Umbilical cord blood is the only source of stem cells
Correct Answer: B
Rationale: Autologous transplantation uses the patient's own stem
cells, which are collected during remission, cryopreserved, and
reinfused after high-dose conditioning therapy. This approach
eliminates the risk of graft-versus-host disease .
Q4. A patient with multiple myeloma is scheduled for an
autologous stem cell transplant. The nurse understands that
this is the preferred transplant type for this diagnosis because:
A. Myeloma is highly responsive to the graft-versus-myeloma
effect
B. Autologous transplant eliminates the risk of GVHD while
allowing dose-intensive therapy
C. Allogeneic transplant is not possible for myeloma patients
D. Autologous transplant requires no conditioning therapy
Correct Answer: B
3
, Rationale: Autologous transplants are often used in multiple
myeloma and certain lymphomas because the patient's own stem
cells can be collected, treated, and reinfused. This approach
eliminates GVHD risk while allowing the delivery of high-dose
therapy .
Q5. The administration of Epstein-Barr virus (EBV) cytotoxic T-
lymphocytes has been found to be a feasible therapeutic
option in which EBV-mediated disease process?
A. Neuroblastoma
B. Lymphoproliferative disease
C. Nasopharyngeal rhabdomyosarcoma
D. Acute lymphocytic leukemia
Correct Answer: B
Rationale: Clinical studies have demonstrated the feasibility and
safety of administering Epstein-Barr virus (EBV) cytotoxic T-
lymphocytes (CTL) to prevent and treat EBV lymphoproliferative
disease in post-allogeneic transplant patients .
4
